Dana-Farber/Boston Children's Cancer and Blood Disorders Center in Boston, MA, treats all kidney (renal) tumors occurring in children and young adults, including:
Our kidney tumor specialists and surgeons are known for treating children with the most complex cases, as well as for their expertise in delivering specialized treatments, including stem cell transplantation.
Through Dana-Farber/Boston Children’s, children with kidney tumors receive treatment at both Dana-Farber Cancer Institute and Boston Children's Hospital. Our cancer specialists from Dana-Farber work closely with the pediatric experts at Boston Children's to ensure every aspect of your child's health is overseen before, during and after their treatment.
Dana-Farber/Boston Children's patients have access to the broadest set of pediatric and oncologic expertise available. The breadth of our expertise allows us to assemble a team of specialists to meet the specific needs of each patient.
At the core of the treatment team is a medical oncologist who specializes in treating kidney tumors. Many of our physicians are also active researchers, so our patients have access to the very best and up-to-date treatments available.
Your child’s treatment team will include:
Other key members of the treatment team include experts who help the child prepare for life during and after treatment, including psychiatrists and psychologists, child life specialists, social workers, nutritionists, and school specialists.
Members of our Kidney Tumor Program also oversee laboratory and clinical research designed to improve understanding and treatment of childhood kidney tumors.
Because Dana-Farber/Boston Children’s Cancer and Blood Disorders Center is the regional Phase I center for the Children's Oncology Group, a collaborative research organization dedicated to improving the treatment of childhood cancers, our center offers treatments unavailable at other regional institutions. We also collaborate with other pediatric centers across the country to offer unique treatment options.
Our current research includes:
Our researchers are also global leaders in the basic and translational study of rhabdoid tumors, including malignant rhabdoid tumor and atypical teratoid/rhabdoid tumor. Their goal: to understand the biological basis of rhabdoid tumors, including the role(s) of mutations in the gene SMARCB1, and to develop more effective treatment methods for children with these tumors.
In addition, we have a phase I clinical trial open for children with refractory or relapsed malignant rhabdoid tumor, as well as access to any tumor trials available through the Children's Oncology Group.
Rated the top pediatriccancer center by U.S. News & World Report